Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;42(4):827-836.
doi: 10.1007/s10875-022-01237-1. Epub 2022 Mar 15.

X-Linked Agammaglobulinemia: Infection Frequency and Infection-Related Mortality in the USIDNET Registry

Affiliations

X-Linked Agammaglobulinemia: Infection Frequency and Infection-Related Mortality in the USIDNET Registry

Dana O'Toole et al. J Clin Immunol. 2022 May.

Abstract

X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disorder caused by mutations in the Bruton tyrosine kinase (BTK) gene leading to B lymphocyte deficiency and susceptibility to infection. A potential benefit of earlier diagnosis and treatment initiation on morbidity and mortality in XLA is incompletely understood. In the USIDNET Registry, we describe infection frequency and infection-related mortality in patients with XLA and their relationship to age of diagnosis and treatment initiation. Among the 231 XLA patients enrolled in the Registry, respiratory infections (N = 203, 88%) were the most commonly reported. Among those deceased (N = 20) where cause of death was known (N = 17), mortality was attributed to infection in most (N = 12, 71%). Chronic lung disease, often a consequence of repeated lower respiratory tract infection (LRTI), was also a frequent complication associated with mortality (N = 9, 53%). Age of diagnosis in years was lower for those without LRTI compared to those with (median 1.5 [IQR 0.5-3.3] vs. median 3.0 [IQR 1.0-5.0], p = 0.0026) and among living patients compared to deceased (median 1.8 [IQR 0.5-5.0] vs. median 2.7 [IQR 1.6-6.0], p = 0.04). Age at treatment initiation in years was lower among those without LRTIs compared to those with (median 1.0 [IQR 0.4-2.4] vs. median 2.8 [IQR 1.0-5.4], p = 0.0006). For every year increase in age at start of therapy, the odds of experiencing a LRTI was 1.216 (OR 1.216, 95% CI 1.048-1.411, p = 0.01). Given the expected finding of reduced LRTIs and mortality among those with earlier age at diagnosis, our study findings support inclusion of XLA in newborn screening programs.

Keywords: Immunoglobulin; Infection; Infectious organism; Primary immunodeficiency; USIDNET; X-linked agammaglobulinemia.

PubMed Disclaimer

Conflict of interest statement

Dr. Kathleen E. Sullivan is a consultant for the Immune Deficiency Foundation and Enzyvant and is an editor for Elsevier and Uptodate. The remaining authors declare they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Birth year among 231 patients with X-linked agammaglobulinemia from the USIDNET Registry
Fig. 2
Fig. 2
Scatter plot of birth year and diagnosis age among 231 patients with X-linked agammaglobulinemia in the USIDNET Registry

References

    1. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–728. doi: 10.1542/peds.9.6.722. - DOI - PubMed
    1. Conley ME, Brown P, Pickard AR, Buckley RH, Miller DS, Raskind WH, et al. Expression of the gene defect in X-linked agammaglobulinemia. N Engl J Med. 1986;315(9):564–567. doi: 10.1056/NEJM198608283150907. - DOI - PubMed
    1. Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J. Mutations in BTK in patients with presumed X-linked agammaglobulinemia. Am J Hum Genet. 1998;62(5):1034–1043. doi: 10.1086/301828. - DOI - PMC - PubMed
    1. Ochs HD, Smith CI. X-linked agammaglobulinemia. A clinical and molecular analysis. Medicine (Baltimore) 1996;75(6):287–299. doi: 10.1097/00005792-199611000-00001. - DOI - PubMed
    1. El-Sayed ZA, Abramova I, Aldave JC, Al-Herz W, Bezrodnik L, Boukari R, et al. X-linked agammaglobulinemia (XLA): phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J. 2019;12(3):100018. doi: 10.1016/j.waojou.2019.100018. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources